FamiCord (V3V) investor relations material

Executive summary

• Group revenues rose 7.3% year-over-year to €88.2 million in 2025, reflecting operational streamlining and positive business progression.

• EBITDA increased 12.3% to €10.6 million, with the margin improving to 12.0% for the year.

• Net income from continuing operations turned negative at €-5.0 million due to substantial non-cash goodwill impairments.

• Operational focus shifted further to core family stem cell banking, with CAR-T cell therapy activities deprioritized and reported as discontinued operations.

Financial highlights

• Gross profit grew 22.0% year-over-year to €47.0 million, driven by price adjustments and cost control.

• Net invoiced B2C services increased 1.5% to €74.7 million, with recurring payments up 7.0% to €22.7 million.

• Operating cash flow declined 58.5% to €3.6 million, mainly due to a shift toward subscription contracts.

• Cash and cash equivalents fell 29.4% to €11.9 million at year-end.

Outlook and guidance

• Revenue for 2026 is forecasted between €80–90 million, with EBITDA expected in the €9.0–11.0 million range, assuming stable exchange rates.

• Management anticipates continued consumer reluctance and subdued new customer business due to macroeconomic and geopolitical uncertainties.